大腸がんスクリーニング・診断市場：タイプ、製品、用途、エンドユーザー別-2025-2030年の世界予測

大腸がんスクリーニング・診断市場の2024年の市場規模は18億6,000万米ドルで、2025年には19億9,000万米ドル、CAGR 7.41%で成長し、2030年には28億6,000万米ドルに達すると予測されています。

大腸がんは依然として世界的に最も重大な健康課題の一つであり、そのスクリーニングと診断プロセスは近年急速な進化を遂げています。本エグゼクティブサマリーでは、技術の進歩、市場動向の変化、消費者ニーズの進化など、このダイナミックな分野における変化の促進要因について詳しく解説します。全体的な情勢は、革新的な診断方法、スクリーニングプロトコルの改善、早期発見と個別化医療の重視の深まりによって特徴付けられています。このような開発は、延命だけでなく、疾病管理と治療へのアプローチも再構築しています。

本書は、意思決定者、業界専門家、ヘルスケア専門家など、市場がどのように変貌しつつあるのかについて理解を深めたい方々を対象としています。本サマリーは、詳細な洞察と実用的な提言を織り交ぜながら、どのような要因が変化を促し、業界利害関係者とヘルスケア提供者の双方がどのような戦略的方向性を検討すべきかについて、権威ある視点を提供しています。各セクションは、この複雑な業界の全体像を描くために、現在の実践、市場セグメンテーション、地域動向、競合環境についての包括的なレビューに基づいています。

大腸がん検診と診断を再定義する変革的シフト

大腸がん検診・診断市場は、先端技術の統合と臨床実践の絶え間ない進化を原動力とする変革的シフトを目の当たりにしています。画像診断と血液スクリーニングの革新は早期発見技術を再定義しました。新しいプロトコールは従来の方法に取って代わりつつあり、精度を高め、不快感や手技のリスクを軽減する患者に優しいソリューションを提供しています。この目覚ましい進歩は、厳格な規制措置、研究資金の増加、予防ヘルスケア戦略の世界の推進によって後押しされています。

技術的ブレークスルーは従来のパラダイムを破壊しつつあります。例えば、画像診断技術の向上は、現在ではより高い解像度と洞察力を提供し、臨床医に以前は見逃されていた微妙な変化を検出する能力を与えています。同様に、血液検査の進歩は、より正確なバイオマーカーをもたらし、早期介入への扉を開いています。このようなシフトは、所要時間を大幅に短縮し、スクリーニングから治療までのペイシェントジャーニーを加速する様々な診断機器や消耗品の導入によって支えられています。

加えて、患者の意識の進化と公衆衛生キャンペーンの高まりが、こうした開発をさらに後押ししています。早期発見のメリットについて国民が知識を深めるにつれ、革新的なスクリーニング検査や診断ソリューションに対する需要が高まっています。このような技術的、規制的、社会的な変化の組み合わせは単なる漸進的なものではなく、市場全体の状況を再定義し、大腸がんがかつてない精度とケアで管理される未来を約束する変革的なものです。

市場セグメンテーションと分析の深掘り

市場を詳細に調査することで、急速な変革の中で明確な方向性を示す明確なセグメンテーションの洞察が明らかになります。市場をタイプ別に見ると、スクリーニング検査と便検査に分けられます。スクリーニング検査は、血液検査と革新的な画像検査に細分化されます。特に画像検査は、大腸内視鏡検査、CTコロノグラフィー、軟性S状結腸内視鏡検査など、それぞれ早期発見と詳細な解剖学的可視化において独自の利点を提供する特殊なモダリティへと発展してきました。一方、便検査は便免疫化学検査、グアイアックベースの便潜血検査、マルチターゲット便DNA検査などの方法に進化し、それぞれ独自の診断精度と患者の利便性を示しています。

製品というプリズムを通して見ると、市場は消耗品と機器に明確に区分されます。消耗品にはキットと試薬の両方が含まれ、診断プロトコルのシームレスな運用を確保する上で重要な役割を果たしています。一方、機器分野にはCTスキャナーや内視鏡などの技術が含まれ、高精度の機器と高度な診断能力が強調されています。このセグメンテーションは、検査の再現性を高める消耗品と、高度な診断精度を提供するハイエンド機器とのバランスを強調するものです。

アプリケーションセグメントを考慮すると、さらに細分化されます。市場は、タイムリーな介入と継続的な患者管理を戦略的に重視することを反映して、疾患モニタリング、早期発見、予後評価に区分されます。これらのアプリケーションは、最初のスクリーニングから継続的な管理まで、ペイシェントジャーニーの各段階がいかに精密なツールと強固な診断サポートに依存しているかを示しています。

最後に、エンドユーザーに基づくセグメンテーションにより、市場の運営力学に関する重要な洞察が得られます。外来手術センター、診断研究所、病院、研究機関を調査した結果、高度な診断およびスクリーニングソリューションに対する需要が広く浸透していることが明らかになりました。各エンドユーザー・セグメントには独自の運用要件があり、中でも病院と診断検査室は、患者ケアにおける中心的役割を担っているため、市場をリードしています。また、外来手術センターや研究機関も、専門的な知識を提供し、技術革新を推進するため、注目度が高まっています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で大腸がんの発生率が上昇
    • 患者における予防ヘルスケアと早期発見の重要性の高まり
    • 国のがん検診プログラムとガイドラインに対する政府の取り組みと資金援助
  • 抑制要因
    • 大腸がん検診に伴う心理的不快感と偏見
  • 機会
    • 世界中でデジタルヘルスツールへの投資が急増
    • 大腸がん診断の精度向上のための人工知能の統合
  • 課題
    • 大腸がん検査ツールの規制承認手続きの遅延
• 市場セグメンテーション分析
  • タイプ：診断と治療の両方の能力があるため、画像検査が好まれる傾向が高まっている
  • 応用：大腸がんのスクリーニングと診断の適用拡大によるがんの早期発見
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 大腸がんスクリーニング・診断市場：タイプ別

• スクリーニング検査
  • 血液検査
  • 画像検査
    • 大腸内視鏡検査
    • CTコロノグラフィー
    • フレキシブルS状結腸鏡検査
• 便検査
  • 便潜血検査
  • グアイアック法による便潜血検査
  • マルチターゲット便DNA検査

第7章 大腸がんスクリーニング・診断市場：製品別

• 消耗品
  • キット
  • 試薬
• 機器
  • CTスキャナー
  • 内視鏡

第8章 大腸がんスクリーニング・診断市場：用途別

• 病気のモニタリング
• 早期発見
• 予後評価

第9章 大腸がんスクリーニング・診断市場：エンドユーザー別

• 外来手術センター
• 診断研究所
• 病院
• 調査機関

第10章 南北アメリカの大腸がんスクリーニング・診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の大腸がんスクリーニング・診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの大腸がんスクリーニング・診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Agilent Technologies, Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Bristol-Myers Squibb Company
• Clinical Genomics Technologies Pty Ltd.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Exact Sciences Corp.
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• GE HealthCare Technologies, Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• KARL STORZ SE & Co. KG
• Medtronic PLC
• Merck KGaA
• Myriad Genetics, Inc.
• Novartis AG
• Novigenix SA
• Olympus Corporation
• Prenetics Global Limited
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Sanofi SA
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET MULTI-CURRENCY
• FIGURE 2. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET MULTI-LANGUAGE
• FIGURE 3. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 4. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 69. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 70. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 71. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 73. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 74. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 116. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 117. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 118. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 120. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 121. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 125. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 126. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 127. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 129. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 130. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 154. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 162. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 163. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 170. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 171. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 172. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 179. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 180. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 188. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 189. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 197. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 263. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 271. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 272. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 277. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 278. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 279. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 280. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
• TABLE 281. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 282. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 283. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 284. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 285. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 286. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
• TABLE 288. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 289. NETHERLANDS COLOR

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 1.86 billion in 2024 and is projected to grow to USD 1.99 billion in 2025, with a CAGR of 7.41%, reaching USD 2.86 billion by 2030.

Colorectal cancer remains one of the most significant health challenges worldwide, and its screening and diagnostic processes have undergone rapid evolution in recent years. This executive summary provides a detailed look into the drivers of change in this dynamic field, including advancements in technology, shifting market trends, and evolving consumer demands. The overall landscape is marked by innovative diagnostic methods, improved screening protocols, and a deepened focus on early detection and personalized care. These developments are not only extending lives but also reshaping the approach to disease management and treatment.

The narrative that follows is designed for decision-makers, industry experts, and healthcare professionals who require a nuanced understanding of how the market is transforming. By weaving together detailed insights with actionable recommendations, this summary offers an authoritative perspective on what factors are fueling change and what strategic directions both industry stakeholders and healthcare providers should consider. Each section builds on a comprehensive review of current practices, market segmentation, regional trends, and the competitive environment to paint a holistic picture of this complex industry.

Transformative Shifts Redefining Colorectal Cancer Screening and Diagnostics

The colorectal cancer screening and diagnostic market is witnessing transformative shifts driven by the integration of advanced technology and the continuous evolution of clinical practices. Innovations in imaging and blood-based screening have redefined early detection techniques. New protocols are rapidly replacing traditional methods, offering enhanced accuracy and patient-friendly solutions that reduce discomfort and procedural risks. This remarkable progression is bolstered by stringent regulatory measures, increased research funding, and a global push towards more preventive healthcare strategies.

Technological breakthroughs are disrupting conventional paradigms. For example, enhanced imaging techniques now provide greater resolution and insight, giving clinicians the ability to detect subtle changes that were previously missed. Similarly, advancements in blood tests have led to more accurate biomarkers, opening doors to earlier interventions. These shifts are supported by the introduction of a range of diagnostic instruments and consumables that significantly reduce turnaround times, thereby accelerating the patient journey from screening to treatment.

In addition, evolving patient awareness and increasing public health campaigns have further catalyzed these developments. As populations become more informed about the benefits of early detection, the demand for innovative screening tests and diagnostic solutions is on the rise. This combination of technological, regulatory, and societal changes is not merely incremental but transformative, redefining the overall market landscape and promising a future where colorectal cancer is managed with unprecedented precision and care.

Deep Dive into Market Segmentation and Analysis

A meticulous examination of the market uncovers distinct segmentation insights that offer clarity and direction amid rapid transformation. When considering the market under the lens of type, the landscape is divided into an array of screening tests and stool tests. The screening tests segment itself is nuanced by further subdivisions into blood tests and innovative imaging tests. Particularly, imaging tests have evolved into specialized modalities including colonoscopy, CT colonography, and flexible sigmoidoscopy - each offering unique advantages in early detection and detailed anatomical visualization. On the other hand, stool tests have evolved to include methods such as the fecal immunochemical test, guaiac-based fecal occult blood test, and multitarget stool DNA testing, each demonstrating distinct diagnostic accuracy and patient convenience.

When viewed through the prism of products, the market is clearly delineated into consumables and instruments. Consumables, which include both kits and reagents, play a critical role in ensuring the seamless operation of diagnostic protocols, while the instrument segment, encompassing technologies such as CT scanners and endoscopes, highlights the emphasis on high-precision equipment and advanced diagnostic capabilities. This formation of segmentation underscores the balance between consumable supplies that drive the repeatability of tests and high-end instruments which offer advanced diagnostic accuracy.

Further granularity is achieved when the application segment is considered. The market is segmented into disease monitoring, early detection, and prognosis assessment, reflecting a strategic emphasis on timely interventions and continuous patient management. These applications illustrate how each stage of the patient's journey-from initial screening to ongoing management-relies on precision tools and robust diagnostic support.

Finally, the segmentation based on end user provides critical insights into the operational dynamics of the market. With the market studied across ambulatory surgical centers, diagnostics laboratories, hospitals, and research institutes, it is evident that the demand for advanced diagnostic and screening solutions is pervasive. Each end user segment has unique operational requirements, with hospitals and diagnostic laboratories leading the charge due to their central role in patient care. Ambulatory surgical centers and research institutes are also gaining increased attention as they contribute specialized expertise and drive innovation.

Based on Type, market is studied across Screening Tests and Stool Tests. The Screening Tests is further studied across Blood Tests and Imaging Tests. The Imaging Tests is further studied across Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. The Stool Tests is further studied across Fecal Immunochemical Test, Guaiac-Based Fecal Occult Blood Test, and Multitarget Stool DNA Testing.

Based on Product, market is studied across Consumables and Instruments. The Consumables is further studied across Kits and Reagents. The Instruments is further studied across CT Scanners and Endoscopes.

Based on Application, market is studied across Disease Monitoring, Early Detection, and Prognosis Assessment.

Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes.

Regional Trends Shaping the Diagnostic Landscape

Understanding the market's regional dynamics is essential to capturing the breadth of change occurring in colorectal cancer screening and diagnostics. In the Americas, rapid technological adoption and a proactive approach to health policy have created an environment where advanced diagnostic techniques are quickly integrated into clinical practice. Health systems in this region are increasingly investing in state-of-the-art screening procedures that emphasize early detection and improved patient outcomes.

In the region encompassing Europe, the Middle East, and Africa, there is a confluence of historically strong healthcare frameworks with an increasing appetite for innovation. Enhanced investment in research and development, along with robust regulatory support, nudges the market towards a more conservative yet steady adoption of new technologies. Differing economic landscapes and healthcare policies drive specific localized strategies that cater effectively to patient demographics and disease prevalence patterns.

The Asia-Pacific region, characterized by its rapid economic growth and expanding healthcare infrastructure, is emerging as a focal point for colorectal cancer diagnostics. Here, a growing middle class and increased government healthcare initiatives facilitate the widespread implementation of advanced screening tests and diagnostic instruments. This region sees a unique blend of traditional healthcare practices with modern diagnostic technologies, supporting a coherent strategy that addresses both early detection and ongoing disease management. Collectively, these regional insights illustrate how geographic nuances contribute to tailored market strategies and influence global investment decisions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Company Insights Influencing Market Evolution

The competitive landscape of colorectal cancer diagnostics is driven by a host of companies that are at the forefront of medical innovation and technological differentiation. Market leaders such as Abbott Laboratories and AbbVie Inc. provide a strong foundation through diversified portfolio offerings, emphasizing reliability and clinical efficacy. Recognized giants like Agilent Technologies, Inc. and Bayer AG have innovated extensively in imaging and diagnostic reagents, setting high benchmarks for emerging players. Companies including Becton, Dickinson and Company and Bio-Rad Laboratories, Inc. have leveraged their widespread operational networks to drive faster diagnostics and improved screening solutions.

The role of organizations like bioMerieux SA and Bristol-Myers Squibb Company is increasingly significant, as their research-driven breakthroughs continue to influence diagnostic protocols. Clinical Genomics Technologies Pty Ltd. and Eiken Chemical Co., Ltd. introduce niche and specialized solutions that add depth to the diagnostic toolkit. The contributions from Epigenomics AG and Exact Sciences Corp. are noteworthy; these companies are instrumental in transforming early detection strategies with a focus on genetic and molecular indicators.

Global leaders such as F. Hoffmann-La Roche Ltd. and Fujifilm Holdings Corporation have made notable advances with imaging solutions and broader diagnostic applications. GE HealthCare Technologies, Inc., along with Guardant Health, Inc., have expanded the frontier of precision diagnostics through a combination of advanced equipment and innovative screening methodologies. Hologic, Inc., Illumina, Inc., and KARL STORZ SE & Co. KG further consolidate the competitive landscape with their continued advancements in endoscopic and genomics-based technologies. Additionally, Medtronic PLC and Merck KGaA commit substantial resources to integrate diagnostic instruments into broader clinical pathways.

Not to be overlooked, companies like Myriad Genetics, Inc. and Novartis AG stand out for their research and personalized medicine approaches, while emerging players such as Novigenix SA and Olympus Corporation offer disruptive solutions that challenge existing paradigms. The industry is further enriched by contributions from Prenetics Global Limited and QIAGEN N.V., whose precision-based tools are instrumental in refining diagnostic accuracy. Quest Diagnostics Incorporated, Sanofi SA, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. round out this dynamic ecosystem, ensuring that innovation, quality, and efficacy remain at the heart of new product development and market expansion.

The report delves into recent significant developments in the Colorectal Cancer Screening & Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Clinical Genomics Technologies Pty Ltd., Eiken Chemical Co., Ltd., Epigenomics AG, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Guardant Health, Inc., Hologic, Inc., Illumina, Inc., KARL STORZ SE & Co. KG, Medtronic PLC, Merck KGaA, Myriad Genetics, Inc., Novartis AG, Novigenix SA, Olympus Corporation, Prenetics Global Limited, QIAGEN N.V., Quest Diagnostics Incorporated, Sanofi SA, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.. Strategic Recommendations for Industry Players to Drive Future Growth

To navigate the rapidly evolving landscape, industry leaders must adopt a proactive approach that blends innovation with strategic investments. First, fostering robust research collaborations across academic and clinical institutions can accelerate the development of next-generation diagnostic technologies. Investment in digital transformation, including the integration of artificial intelligence and machine learning, is crucial in enhancing the speed and accuracy of diagnostic tools. These investments not only improve patient outcomes but also serve as a catalyst for operational efficiency throughout the healthcare continuum.

Leveraging real-world data and fostering a feedback loop between clinical practices and research becomes paramount. By engaging closely with end users such as hospitals, diagnostics laboratories, and ambulatory surgical centers, companies can develop products that directly respond to clinical needs and improve overall diagnostic accuracy. Furthermore, tailoring product development to regional specifics in the Americas, Europe, Middle East & Africa, and Asia-Pacific ensures that innovations are both cost-effective and aligned with local healthcare dynamics.

Industry players are encouraged to pursue strategic alliances and mergers that can bridge gaps between diagnostic consumables and advanced imaging instruments. A balanced portfolio that caters to both consumables and high-end instruments is essential to capture the full market potential. This approach involves continuously updating existing product lines, pursuing regulatory approvals for novel technologies, and exploring innovative reimbursement models that incentivize early detection and disease management.

In parallel, expanding market presence through targeted regional strategies will ensure a broader reach and improved market penetration. Emphasizing patient-centric approaches that incorporate wellness programs, preventive care initiatives, and community outreach can further solidify a company's brand reputation while creating sustainable revenue streams. A forward-thinking strategic roadmap involving digital innovation, enhanced clinical partnerships, and regional customization will enable industry leaders to maintain their competitive edge in the evolving diagnostic landscape.

Summative Conclusions on the Evolving Diagnostic Paradigm

The analytical journey through the colorectal cancer screening and diagnostic field highlights a rapidly evolving landscape defined by significant technological advancements, shifting market dynamics, and heightened competitive fervor. Significant progress in screening and diagnostic methodologies, from advanced imaging tests to innovative stool tests, underscores the market's response to the escalating demand for early detection and continuous disease monitoring. The segmentation analysis further reveals a complex matrix where types, products, applications, and end users play interdependent roles in shaping market strategies.

Regional variations contribute unique challenges and opportunities, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each offering distinct pathways for growth and innovation. This diversity in regional profiles not only demands tailored approaches but also encourages cross-market synergies that could drive future advancements in diagnostic technology.

The competitive landscape, marked by industry behemoths alongside nimble innovators, reflects an ecosystem built on continuous improvement and collaborative initiatives. Together, these insights underscore the need for a dual focus on technology and strategy. The sector must dynamically embrace change while rigorously balancing clinical efficacy with market expansion strategies. Ultimately, the integration of advanced diagnostic tools with strategic partnerships is key to paving the way for a future where colorectal cancer is detected with greater precision and managed more effectively.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of colorectal cancer cases worldwide
    • 5.1.1.2. Growing emphasis on preventive healthcare and early detection among patients
    • 5.1.1.3. Government initiatives and funding support for national cancer screening programs and guidelines
  • 5.1.2. Restraints
    • 5.1.2.1. Psychological discomfort and stigma associated with colorectal cancer screening procedures
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in investments in digital health tools worldwide
    • 5.1.3.2. Integration of artificial intelligence for enhanced accuracy in colorectal cancer diagnosis
  • 5.1.4. Challenges
    • 5.1.4.1. Delayed regulatory approval procedures for colorectal cancer screening tools
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing preference for imaging tests due to its dual diagnostic and therapeutic capability
  • 5.2.2. Application: Expanding application of colorectal cancer screening and diagnostics for early cancer detection
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Colorectal Cancer Screening & Diagnostic Market, by Type

• 6.1. Introduction
• 6.2. Screening Tests
  • 6.2.1. Blood Tests
  • 6.2.2. Imaging Tests
    • 6.2.2.1. Colonoscopy
    • 6.2.2.2. CT Colonography
    • 6.2.2.3. Flexible Sigmoidoscopy
• 6.3. Stool Tests
  • 6.3.1. Fecal Immunochemical Test
  • 6.3.2. Guaiac-Based Fecal Occult Blood Test
  • 6.3.3. Multitarget Stool DNA Testing

7. Colorectal Cancer Screening & Diagnostic Market, by Product

• 7.1. Introduction
• 7.2. Consumables
  • 7.2.1. Kits
  • 7.2.2. Reagents
• 7.3. Instruments
  • 7.3.1. CT Scanners
  • 7.3.2. Endoscopes

8. Colorectal Cancer Screening & Diagnostic Market, by Application

• 8.1. Introduction
• 8.2. Disease Monitoring
• 8.3. Early Detection
• 8.4. Prognosis Assessment

9. Colorectal Cancer Screening & Diagnostic Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Diagnostics Laboratories
• 9.4. Hospitals
• 9.5. Research Institutes

10. Americas Colorectal Cancer Screening & Diagnostic Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Colorectal Cancer Screening & Diagnostic Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Colorectal Cancer Screening & Diagnostic Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. ColoWatch and Bracco Diagnostics partner to expand the availability of virtual colonoscopy for the early detection of colon and rectal cancer
  • 13.3.2. Owkin and Roche collaborate on MSIntuit CRC v2 to enhance colorectal cancer diagnosis through AI advancements
  • 13.3.3. FDA approval of Cologuard Plus enhances colorectal cancer screening with improved sensitivity and specificity
  • 13.3.4. FDA approval of Guardant Shield blood test enhances colorectal cancer screening with non-invasive option
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Agilent Technologies, Inc.
• 4. Bayer AG
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. bioMerieux SA
• 8. Bristol-Myers Squibb Company
• 9. Clinical Genomics Technologies Pty Ltd.
• 10. Eiken Chemical Co., Ltd.
• 11. Epigenomics AG
• 12. Exact Sciences Corp.
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fujifilm Holdings Corporation
• 15. GE HealthCare Technologies, Inc.
• 16. Guardant Health, Inc.
• 17. Hologic, Inc.
• 18. Illumina, Inc.
• 19. KARL STORZ SE & Co. KG
• 20. Medtronic PLC
• 21. Merck KGaA
• 22. Myriad Genetics, Inc.
• 23. Novartis AG
• 24. Novigenix SA
• 25. Olympus Corporation
• 26. Prenetics Global Limited
• 27. QIAGEN N.V.
• 28. Quest Diagnostics Incorporated
• 29. Sanofi SA
• 30. Siemens AG
• 31. Sysmex Corporation
• 32. Thermo Fisher Scientific Inc.